NCT05500807View on ClinicalTrials.gov

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2027

Conditions
Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia
Interventions
DRUG

Emicizumab

Subcutaneous injection of emicizumab for prophylaxis

Trial Locations (9)

33146

RECRUITING

University of Miami - Miller School of Medicine, Coral Gables

33607

RECRUITING

St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders, Tampa

46260

RECRUITING

Innovative Hematology, Inc. (IHI), Indianapolis

48109

RECRUITING

University of Michigan Medical School, Ann Arbor

48859

RECRUITING

Central Michigan University: Children's Hospital of Michigan, Mount Pleasant

61614

RECRUITING

Bleeding and Clotting Disorders Institute (BCDI), Peoria

92868

RECRUITING

The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD), Orange

94063

RECRUITING

Stanford University: Stanford Children's Health, Redwood City

98101

RECRUITING

Washington Center for Bleeding Disorders, Seattle

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Bleeding and Clotting Disorders Institute Peoria, Illinois

OTHER

NCT05500807 - Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | Biotech Hunter | Biotech Hunter